Abstract: Nucleic acid aptamers that bind to tumor necrosis factor alpha (TNF). Also provided herein are pharmaceutical compositions comprising such anti-TNF aptamers and methods for the using the same for therapeutic and diagnostic applications, for example, alleviating liver injury and monitoring presence of TNF in vivo or in vitro.

Abstract: Nucleic acid aptamers that bind to tumor necrosis factor alpha (TNF). Also provided herein are pharmaceutical compositions comprising such anti-TNF aptamers and methods for the using the same for therapeutic and diagnostic applications, for example, alleviating liver injury and monitoring presence of TNF in vivo or in vitro.

Abstract: Aptamers that bind to and antagonize PDL1 and uses thereof in enhancing immune activity (e.g., promoting T cell proliferation), treating cancer, and/or infectious diseases such as infections caused by enterovirus, HBV, or HCV infection.

Abstract: Aptamers that bind to and antagonize programmed cell death protein 1 (PD-1). Also provided herein are pharmaceutical compositions comprising such anti-PD-1 aptamers and methods for using the same for promoting T cell proliferation, treating cancer or infectious diseases, such as human immunodeficiency virus (HIV) infection.

Abstract: Aptamers that bind to and antagonize PDL1 and uses thereof in enhancing immune activity (e.g., promoting T cell proliferation), treating cancer, and/or infectious diseases such as infections caused by enterovirus, HBV, or HCV infection.

Abstract: The invention provides DNAzymes which are capable to silence the expression of EGFR at allele-specific level. These allele-specific DNAzymes against EGFR T790M mutation will knockdown the expression of EGFR T790M mRNA while keeping EGFR wild-type mRNA intact. Hence, these allele-specific DNAzymes against EGFR T790M mutation may overcome T790M-derived TKI resistance accompanied with lower unwanted side effects on normal cells in lung cancer patients.

Abstract: Aptamers that bind to and antagonize PD-1 and uses thereof in promoting T cell proliferation, treating cancer or infectious diseases such as HIV infection.

Abstract: A producing method of a tooth model for clinic practice having steps of: obtaining a tooth data, wherein the tooth data comprises inner and outer appearance and size of a real tooth; 3D printing a semi-finished tooth model according to the tooth data by using a first material and a second material, the first and second material is cured by light when 3D printing; wherein the semi-finished tooth model has a tooth body, a tooth pulp portion and a sacrificial portion; the tooth body is covered by the sacrificial portion and the tooth pulp portion is covered by the tooth body; the tooth body and the tooth pulp portion having a crown part at the top and a least one root part at the bottom of the semi-finished tooth model; the tooth pulp portion is in tube shape which is gradually contracted from the crown part to the root part; the tooth body is printed by using the first material and the tooth pulp portion and the sacrificial portion are printed by using the second material; the first material has greater mechani

Abstract: The invention provides DNAzymes which are capable to silence the expression of EGFR at allele-specific level. These allele-specific DNAzymes against EGFR T790M mutation will knockdown the expression of EGFR T790M mRNA while keeping EGFR wild-type mRNA intact. Hence, these allele-specific DNAzymes against EGFR T790M mutation may overcome T790M-derived TKI resistance accompanied with lower unwanted side effects on normal cells in lung cancer patients.